^
Association details:
| Biomarker: | HER-2 Y772_A775dup |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Vizimpro (dacomitinib) (pan-HER inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors
Excerpt:
Thirteen tumors harbored identical 12-bp exon 20 insertions [A775_G776insYVMA, alternative nomenclature p.Y772_A775dup(c.2313_2324dup)]...The activity of dacomitinib in patients with HER2 mutations in this trial confirms the earlier reports of benefit with HER2 kinase inhibitors in similar patients.
DOI:
10.1093/annonc/mdv186
Trial ID:
